Abstract
The objective of this study was to evaluate the antitumor efficacy of combined use of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carhonyloxycamptothecin (CPT‐11) and cisplatin (CDDP). The antitumor activities of CPT‐11, CDDP and their combination against 3 human lung tumor xenografts were estimated using congenitally athymic BALB/c (nu/nu) mice. The doses were 47 mg/kg for CPT‐11 and 6 mg/kg for CDDP on days 1, 5 and 9. In combination therapy, half of the single dosage of each agent was used. The doses were administered intraperitoneally. The antitumor activity and toxicity were evaluated in terms of the tumor volume and body weight change of mice, respectively. The combination therapy resulted in a statistically significant tumor regression compared to the use of only CPT‐11 or CDDP in two tumor xenografts out of three. The toxicity of the combination therapy was no higher than that of CPT‐11 or CDDP alone. These results suggest that the antitumor activity of the combination of CPT‐11 and CDDP is superior to that of CPT‐11 or CDDP alone.
Keywords: CPT‐11, Cisplatin, Combination chemotherapy, Nude mouse, Lung cancer
Full Text
The Full Text of this article is available as a PDF (319.3 KB).
REFERENCES
- 1. ) Kunimoto , T. , Nitta , K. , Tanaka , T. , Uehara , N. , Baba , H. , Takeuchi , M. , Yokokura , T. , Sawada , S. , Miyasaka , T. and Mutai , M.Antitumor activity of 7‐ethyl‐10‐[4‐(1‐piperidino)‐l‐piperidino]carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors . Cancer Res. , 47 , 5944 – 5947 ( 1987. ). [PubMed] [Google Scholar]
- 2. ) Matsuzaki , T. , Yokokura , T. , Mutai , M. and Tsuruo , T.Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT‐11, in mice . Cancer Chemother. Pharmacol. , 21 , 308 – 312 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 3. ) Negoro , S. , Fukuoka , M. , Masuda , N. , Takada , M. , Kusunoki , Y. , Matsui , K. , Takifuji , N. , Kudoh , S. , Niitani , H. and Taguchi , T.Phase I study of weekly intravenous infusions of CPT‐11, a new derivative of camptothecin, in the treatment of advanced non‐small‐cell lung cancer . J. Natl. Cancer Inst. , 83 , 1164 – 1168 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Fukuoka , M. , Niitani , H. , Suzuki , A. , Motomiya , M. , Hasegawa , K. , Nishiwaki , Y. , Kuriyama , T. , Ariyoshi , Y. , Negoro , S. , Masuda , N. , Nakajima , S. and Taguchi , T.A phase II study of CPT‐11, a new derivative of camptothecin, for previously untreated non‐small‐cell lung cancer . J. Clin. Oncol. , 10 , 16 – 20 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 5. ) Negoro , S. , Fukuoka , M. , Niitani , H. and Taguchi , T.Phase II study of CPT‐11, new camptothecin derivative, in small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. , 10 , 241 ( 1991. ). [Google Scholar]
- 6. ) Kaneda , N. , Nagata , H. , Furuta , T. and Yokokura , T.Metabolism and pharmacokinetics of the camptothecin analogue CPT‐11 in the mouse . Cancer Res. , 50 , 1715 – 1720 ( 1990. ). [PubMed] [Google Scholar]
- 7. ) Takada , M. , Fukuoka , M. , Kudoh , S. , Masuda , N. , Nakagawa , K. and Kishimoto , S.Synergistic effects of CPT‐11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice . Proc. Am. Assoc. Cancer Res. , 33 , 226 ( 1992. ). [Google Scholar]
- 8. ) Goldin , A. , Venditti , J. M. , Macdonald , J. S. , Muggid , F. M. , Henney , J. E. and Devita , V.T. , Jr.Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute . Eur. J. Cancer , 17 , 129 – 142 ( 1981. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Ohno , R. , Okada , K. , Masaoka , T. , Kuramoto , A. , Arima , T. , Yoshida , Y. , Ariyoshi , H. , Ichimaru , M. , Sakai , Y. , Oguro , M. , Ito , Y. , Morishima , Y. , Yokomaku , S. and Ota , K.An early phase II study of CPT‐11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma . J. Clin. Oncol. , 8 , 1907 – 1912 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 10. ) Ning , S. and Hahn , G. M.Combination therapy: lonida‐mine, hyperthermia, and chemotherapy against the RIF‐1 tumor in vivo . Cancer Res. , 51 , 5910 – 5914 ( 1991. ). [PubMed] [Google Scholar]
- 11. ) Krosnick , J. A. , Mulé , J. J. , McIntosh , J. K. and Rosenberg , S. A.Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo . Cancer Res. , 49 , 3729 – 3733 ( 1989. ). [PubMed] [Google Scholar]
- 12. ) Hida , S. , Okada , K. and Yoshida , O.Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts . Jpn. J. Cancer Res. , 81 , 425 – 430 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. ) Fujita , F. , Fujita , M. , Shimozuma , K. and Taguchi , T.Combination chemotherapy of human gastrointestinal and breast cancer xenografts in nude mice with 5′‐deoxy‐5‐fluorouridine and mitomycin C . J. Jpn. Soc. Cancer Ther. , 21 , 1386 – 1396 ( 1986. ) ( in Japanese ). [PubMed] [Google Scholar]
- 14. ) Hsiang , Y. H. , Hertzberg , R. , Hecht , S. and Liu , L.Camptothecin induces protein‐linked DNA breaks via mammalian DNA topoisomerase I . J. Biol. Chem. , 260 , 14873 – 14878 ( 1985. ). [PubMed] [Google Scholar]
- 15. ) Lippard , S. J.Overview . In “ Platinum Coordination Complexes in Cancer Chemotherapy ,” ed. Hacker M. P. , Douple E. B. and Krakoff I. H. , pp. 11 – 13 ( 1984. ). Martinus Nijhoff Publishing; , Boston . [Google Scholar]